It may have made a modest start with Suprax, but today the brand business of Lupin is growing close to 70 - 80 pct. After having bought Antara from Oscient, made by Ethypharm on its platform technology, it is now fully poised to enter the branded markets with Oral Contraceptives and Liquid formulations.
Suprax marked the beginning of a new era at Lupin. After Suprax there was no looking back. The best part of Lupin is the professional management. The promoter family is involved, but both Nilesh and Vinita ( more involved with the US market) are very professional.
With 105 ANDAs filed and 35 approved, the company is poised to grow fast on the US market.
The company is not fighting shy of investments either. Oral contraceptives, which the company is now getting into, and has filed about 7 ANDAs for, as per the new guidelines will usually all call for a CT. The cost of the CT could well be USD 10 - 15 Mn depending upon the product and subjects. So the company is getting into high value and difficult to make products.
I hope Lupin, which indeed was one of the benefactors of the debacle that happened at Ranbaxy, will restore the glory that Indian Pharma lost.
No comments:
Post a Comment